Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
暂无分享,去创建一个
[1] F. Penin,et al. Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. , 2009, Biochemical and biophysical research communications.
[2] Ralf Bartenschlager,et al. Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly , 2008, PLoS pathogens.
[3] T. Tellinghuisen,et al. Regulation of Hepatitis C Virion Production via Phosphorylation of the NS5A Protein , 2008, PLoS pathogens.
[4] Min Gao,et al. Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System , 2010, Antimicrobial Agents and Chemotherapy.
[5] M. Gao,et al. Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052 , 2011, Journal of Virology.
[6] R. Nettles,et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS‐790052 , 2012, Hepatology.
[7] C. Rice,et al. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[8] Min Gao,et al. Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 , 2011, Hepatology.
[9] M. Buti,et al. 2003 ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS , 2010 .
[10] Xin Huang,et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations , 2011, Hepatology.
[11] H. Yoon,et al. Domain 2 of nonstructural protein 5A (NS5A) of hepatitis C virus is natively unfolded. , 2007, Biochemistry.
[12] H. Mo,et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. , 2012, Journal of hepatology.
[13] M. Gao,et al. Intragenic Complementation of Hepatitis C Virus NS5A RNA Replication-Defective Alleles , 2012, Journal of Virology.
[14] Ralf Bartenschlager,et al. Quantitative Analysis of the Hepatitis C Virus Replication Complex , 2005, Journal of Virology.
[15] U. Koch,et al. Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. , 2009, Bioorganic & medicinal chemistry letters.
[16] J. Arnold,et al. Hepatitis C Virus Nonstructural Protein 5A (NS5A) Is an RNA-binding Protein* , 2005, Journal of Biological Chemistry.
[17] M. Elazar,et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. , 2011, Virology.
[18] A. Agarwal,et al. 876 ACH-3102, A SECOND GENERATION NS5A INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY IN PATIENTS WITH GENOTYPE 1a HCV INFECTION DESPITE THE PRESENCE OF BASELINE NS5A-RESISTANT VARIANTS , 2013 .
[19] Huiling Yang,et al. 1191 GS-5816, A SECOND GENERATION HCV NS5A INHIBITOR WITH POTENT ANTIVIRAL ACTIVITY, BROAD GENOTYPIC COVERAGE AND A HIGH RESISTANCE BARRIER , 2013 .
[20] N. Meanwell,et al. Identification of Hepatitis C Virus NS5A Inhibitors , 2009, Journal of Virology.
[21] C. Rice,et al. Identification of Residues Required for RNA Replication in Domains II and III of the Hepatitis C Virus NS5A Protein , 2007, Journal of Virology.
[22] David Pryde,et al. Small Molecules Targeting Hepatitis C Virus-Encoded NS5A Cause Subcellular Redistribution of Their Target: Insights into Compound Modes of Action , 2011, Journal of Virology.
[23] Libin Rong,et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life , 2013, Proceedings of the National Academy of Sciences.
[24] C. Rice,et al. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase , 2005, Nature.
[25] Seng-Lai Tan,et al. NS5A--from obscurity to new target for HCV therapy. , 2008, Recent patents on anti-infective drug discovery.
[26] M. Hickey,et al. Crystal Structure of a Novel Dimeric Form of NS5A Domain I Protein from Hepatitis C Virus , 2009, Journal of Virology.
[27] Min Gao,et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect , 2010, Nature.
[28] Charles M. Rice,et al. The NS5A Protein of Hepatitis C Virus Is a Zinc Metalloprotein* , 2004, Journal of Biological Chemistry.
[29] R. Bartenschlager,et al. Mutational Analysis of Hepatitis C Virus Nonstructural Protein 5A: Potential Role of Differential Phosphorylation in RNA Replication and Identification of a Genetically Flexible Domain , 2005, Journal of Virology.
[30] Seng-Lai Tan,et al. HCV NS5A: A Multifunctional Regulator of Cellular Pathways and Virus Replication , 2006 .
[31] L. Hamann,et al. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. , 2011, The Journal of general virology.
[32] R. De Francesco,et al. Hyperphosphorylation of the Hepatitis C Virus NS5A Protein Requires an Active NS3 Protease, NS4A, NS4B, and NS5A Encoded on the Same Polyprotein , 1999, Journal of Virology.
[33] Volker Brass,et al. An Amino-terminal Amphipathic α-Helix Mediates Membrane Association of the Hepatitis C Virus Nonstructural Protein 5A* , 2002, The Journal of Biological Chemistry.
[34] C. Cameron,et al. Correlation between NS5A Dimerization and Hepatitis C Virus Replication* , 2012, The Journal of Biological Chemistry.
[35] K. Shimotohno,et al. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. , 1994, Biochemical and biophysical research communications.
[36] Mark Harris,et al. Hepatitis C virus NS5A: tales of a promiscuous protein. , 2004, The Journal of general virology.
[37] Jason A. Wiles,et al. 845 PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION OF NS5A INHIBITORS , 2012 .
[38] N. Stonehouse,et al. All Three Domains of the Hepatitis C Virus Nonstructural NS5A Protein Contribute to RNA Binding , 2010, Journal of Virology.
[39] P. Targett-Adams,et al. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. , 2012, Virus research.
[40] Lingling Jia,et al. In Vitro Activity of BMS-790052 on Hepatitis C Virus Genotype 4 NS5A , 2011, Antimicrobial Agents and Chemotherapy.
[41] W. Delaney,et al. 1172 ANTIVIRAL ACTIVITY AND RESISTANCE PROFILE OF THE NOVEL HCV NS5A INHIBITOR GS-5885 , 2012 .
[42] M. Gao,et al. Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir , 2013, Antimicrobial Agents and Chemotherapy.
[43] Seng-Lai Tan,et al. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? , 2007, Virology.